Engineering and Development

Legal and Compliance

Accounting and Finance

Management and Executive

Customer Service and Support

Chief Human Resources Officer

President

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

Revolution Medicines stock rises after FDA grants Orphan Drug Designation

Revolution Medicines announces U.S. FDA granted ODD to daraxonrasib

Revolution Medicines reports elironrasib data for lung cancer patients

Vice President, Global Value, Access & Pricing

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. They are seeking a Vice President of Global Value, Access & Pricing to lead the Global Market Access & Pricing team, shaping strategies for global market access and pricing while ensuring optimal reimbursement outcomes.

Sign up with Google

Sign in with Google